Bibliographic Details
| Title: |
DETECTING CYP24 EXPRESSION LEVEL AS A MARKER FOR PREDISPOSITION TO CANCER |
| Document Number: |
20100285023 |
| Publication Date: |
November 11, 2010 |
| Appl. No: |
12/633643 |
| Application Filed: |
December 08, 2009 |
| Abstract: |
This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal. |
| Inventors: |
Albertson, Donna G. (Lafayette, CA, US); Pinkel, Daniel (Walnut Creek, CA, US); Collins, Colin (San Rafael, CA, US); Gray, Joe W. (San Francisco, CA, US); Ylstra, Bauke (San Francisco, CA, US) |
| Assignees: |
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA, US) |
| Claim: |
1-32. (canceled) |
| Claim: |
33. A method of treating cancer in an animal, said method comprising: (i) providing a biological sample from said animal; (ii) detecting the level of CYP24 within said biological sample; (iii) comparing said level of CYP24 with a level of CYP24 in a control sample from a normal, cancer-free tissue; and (iv) selecting and performing a cancer therapy in those animals having an increased level of CYP24 compared to the level of CYP24 in said control sample. |
| Claim: |
34. The method of claim 33, wherein said cancer therapy is selected from the group consisting of chemotherapy, radiation therapy, surgery, antihormone therapy, and immunotherapy. |
| Claim: |
35. The method of claim 34, wherein said cancer therapy is an adjuvant cancer therapy. |
| Claim: |
36. The method of claim 33, wherein said level of CYP24 is detected by determining the copy number of CYP24 genes in the cells of said animal. |
| Claim: |
37. The method of claim 36, wherein said copy number of CYP24 genes is determined by hybridization to an array of nucleic acid probes. |
| Claim: |
38. The method of claim 36, wherein said copy number of CYP24 genes is measured using Comparative Genomic Hybridization (CGH). |
| Claim: |
39. The method of claim 26, wherein said Comparative Genomic Hybridization is performed on an array. |
| Claim: |
40. The method of claim 33, wherein said level of CYP24 is detected by measuring the levels of CYP24 mRNA in said biological sample, wherein an increased level of CYP24 RNA in said sample as compared to CYP24 RNA in said control sample indicates the need for an adjuvant cancer therapy. |
| Claim: |
41. The method of claim 40, wherein said level of CYP24 RNA is measured in said biological sample and said control sample at the same vitamin D receptor activity or the activity levels are normalized to the level of vitamin D receptor activity in the sample and control. |
| Claim: |
42. The method of claim 33, wherein said level of CYP24 is detected by measuring the level of CYP24 protein in said biological sample, wherein an increased level of CYP24 protein in said sample as compared to CYP24 protein in said control sample indicates the need for an adjuvant cancer therapy. |
| Claim: |
43. The method of claim 42, wherein said level of CYP24 protein activity is measured in said biological sample and said control sample at the same vitamin D receptor activity or the activity levels are normalized to the level of vitamin D receptor activity in the sample and control. |
| Claim: |
44. The method of claim 33, wherein said CYP24 level is detected by measuring the level of 25-hydroxyvitamin D3 24-hydroxylase enzyme activity in said biological sample wherein an increased level of 25-hydroxyvitamin D3 24-hydroxylase enzyme activity in said sample as compared to 25-hydroxyvitamin D3 24-hydroxylase enzyme activity in said control sample, at a given level of vitamin D receptor activity indicates the need for an adjuvant cancer therapy. |
| Claim: |
45. The method of claim 44, wherein said level 25-hydroxyvitamin D3 24-hydroxylase enzyme activity is measured in said biological sample and said control sample at the same vitamin D receptor activity or the activity levels are normalized to the level of vitamin D receptor activity in the sample and control. |
| Claim: |
46. The method of claim 33, wherein said animal is a mammal selected from the group consisting of humans, non-human primates, canines, felines, murines, bovines, equines, porcines, and lagomorphs. |
| Claim: |
47. The method of claim 33, wherein said biological sample is selected from the group consisting of excised tissue, whole blood, serum, plasma, cerebrospinal fluid, buccal scrape, saliva, and urine. |
| Claim: |
48. The method of claim 33, wherein the difference between said increased level of CYP24 in said biological sample and the level of CYP24 in said control sample is a statistically significant difference. |
| Claim: |
49. The method of claim 33, wherein said increased level of CYP24 in said biological sample is at least about 2-fold greater than the level of CYP24 in said control sample. |
| Claim: |
50. The method of claim 33, wherein said increased level of CYP24 in said biological sample is at least about 4-fold greater than the level of CYP24 in said control sample. |
| Claim: |
51-70. (canceled) |
| Current U.S. Class: |
4241/581 |
| Current International Class: |
61; 61; 61 |
| Accession Number: |
edspap.20100285023 |
| Database: |
USPTO Patent Applications |
